222 related articles for article (PubMed ID: 8940749)
1. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.
Nishimura Y; Nagata Y; Okajima K; Mitsumori M; Hiraoka M; Masunaga S; Ono K; Shoji K; Kojima H
Radiother Oncol; 1996 Sep; 40(3):225-32. PubMed ID: 8940749
[TBL] [Abstract][Full Text] [Related]
2. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
[TBL] [Abstract][Full Text] [Related]
3. Clinical radiobiology of glottic T1 squamous cell carcinoma.
Skladowski K; Tarnawski R; Maciejewski B; Wygoda A; Slosarek K
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):101-6. PubMed ID: 9989520
[TBL] [Abstract][Full Text] [Related]
4. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
Sakata K; Oouchi A; Nagakura H; Akiba H; Tamakawa M; Koito K; Hareyama M; Asakura K; Satoh M; Ohtani S
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):81-8. PubMed ID: 10758308
[TBL] [Abstract][Full Text] [Related]
5. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.
Ricciardelli EJ; Weymuller EA; Koh WJ; Austin-Seymour M; DeSautel MG; Laramore GE
Arch Otolaryngol Head Neck Surg; 1994 Jul; 120(7):737-42. PubMed ID: 8018326
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy in early glottic carcinoma: uni- and multivariate analysis of prognostic factors affecting local control.
Sakata K; Aoki Y; Karasawa K; Hasezawa K; Muta N; Nakagawa K; Terahara A; Onogi Y; Sasaki Y; Akanuma A
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1059-64. PubMed ID: 7961012
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of radiotherapy for T1a and T1bN0M0 glottic carcinoma.
Nomiya T; Nemoto K; Wada H; Takai Y; Yamada S
Laryngoscope; 2008 Aug; 118(8):1417-21. PubMed ID: 18528306
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
Sakata K; Someya M; Hori M; Nakata K; Takagi M; Hareyama M
Strahlenther Onkol; 2008 Jul; 184(7):364-9. PubMed ID: 19016035
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients.
Franchin G; Minatel E; Gobitti C; Talamini R; Vaccher E; Sartor G; Politi D; Trovò MG; Barzan L
Cancer; 2003 Aug; 98(4):765-72. PubMed ID: 12910521
[TBL] [Abstract][Full Text] [Related]
10. Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma.
Nomiya T; Nemoto K; Wada H; Takai Y; Yamada S
Ann Otol Rhinol Laryngol; 2006 Oct; 115(10):727-32. PubMed ID: 17076093
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy in T1-T2 glottic carcinoma: influence of various treatment parameters on local control/complications.
Dinshaw KA; Sharma V; Agarwal JP; Ghosh S; Havaldar R
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):723-35. PubMed ID: 11020569
[TBL] [Abstract][Full Text] [Related]
12. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease.
Cellai E; Frata P; Magrini SM; Paiar F; Barca R; Fondelli S; Polli C; Livi L; Bonetti B; Vitali E; De Stefani A; Buglione M; Biti G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1378-86. PubMed ID: 16095847
[TBL] [Abstract][Full Text] [Related]
13. Significance of pretreatment hemoglobin level in patients with T1 glottic cancer.
Canaday DJ; Regine WF; Mohiuddin M; Zollinger W; Machtay M; Lee J; Schultz D; Rudoltz MS
Radiat Oncol Investig; 1999; 7(1):42-8. PubMed ID: 10030623
[TBL] [Abstract][Full Text] [Related]
14. Decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior commissure extension.
Zouhair A; Azria D; Coucke P; Matzinger O; Bron L; Moeckli R; Do HP; Mirimanoff RO; Ozsahin M
Strahlenther Onkol; 2004 Feb; 180(2):84-90. PubMed ID: 14762660
[TBL] [Abstract][Full Text] [Related]
15. Predicting the local outcome of glottic squamous cell carcinoma after definitive radiation therapy: value of computed tomography-determined tumour parameters.
Hermans R; Van den Bogaert W; Rijnders A; Doornaert P; Baert AL
Radiother Oncol; 1999 Jan; 50(1):39-46. PubMed ID: 10225556
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
17. Survival Impact of Initial Therapy in Patients with T1-T2 Glottic Squamous Cell Carcinoma.
Brady JS; Marchiano E; Kam D; Baredes S; Eloy JA; Park RC
Otolaryngol Head Neck Surg; 2016 Aug; 155(2):257-64. PubMed ID: 27026735
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
[TBL] [Abstract][Full Text] [Related]
19. Definitive radiation therapy for moderately advanced laryngeal cancer: effects of accelerated hyperfractionation.
Okubo M; Nishimura Y; Shibata T; Nakamatsu K; Kanamori S; Tachibana I; Koike R; Nishikawa T; Mori K
Jpn J Clin Oncol; 2010 Oct; 40(10):944-8. PubMed ID: 20534687
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in elderly patients with T1 glottic cancer treated with radiotherapy.
Mucha-Małecka A; Małecki K; Amrogowicz N; Biesaga B; Modrzejewski M
Sci Rep; 2021 Sep; 11(1):17717. PubMed ID: 34489495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
